| HOME >> MEDICINE >> TECHNOLOGY |
5.6 Molecule Profile for Promising Drugs under Clinical Development 57
5.6.1 AVP-923 (Zenvia) 57
5.6.2 Fentora (fentanyl buccal tablet) 58
5.6.3 Nucynta ER (tapentadol) 59
5.6.4 AS-3201 (ranirestat) 60
5.7 Key Takeaway 61
6 Neuropathic Pain Therapeutics: Clinical Trials Mapping 62
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 62
6.2 Clinical Trials by Phase 63
6.3 Clinical Trials by Trial Status 64
6.4 Clinical Trials by Sponsors 65
6.5 Top Companies Participating in Neuropathic Pain Therapeutics Clinical Trials 67
7 Neuropathic Pain Therapeutics - Strategic Assessment 68
7.1 Key Events Impacting the Future Market 68
7.2 Neuropathic Pain Therapeutics: Implications for Future Market Competition 69
8 Neuropathic Pain Therapeutics - Future Players 71
8.1 Introduction 71
8.2 Company Profiles 72
8.2.1 Pfizer Inc. 72
8.2.2 Grunenthal GmbH 76
8.2.3 Avanir Pharmaceuticals 78
8.2.4 Cephalon Inc. 79
8.2.5 Endo Pharmaceuticals 82
8.2.6 Dainippon Sumitomo Pharma Co., Ltd. 84
8.2.7 NeurogesX Inc. 88
8.2.8 Other Companies in the Neuropathic Pain Therapeutics Market 91
9 Neuropathic Pain Therapeutics - Licensing and Partnership Deals 99
10 Neuropathic Pain Therapeutics - Appendix 106
10.1 Market Definitions 106
10.2 Abbreviations 106
10.3 Research Methodology 107
10.3.1 Coverage 108
10.3.2 Secondary Research 108
10.3.3 Forecasting 108
10.3.4 Primary Research 111
10.3.5 Expert Panel Validation 111
10.4 Contact Us 111
10.5 Disclaimer 111
10.6 Bibliography 112
List of Tables
Table 1: Differentiation of Chronic Pain from Acute Pain 7
Table 2: Neuropathic Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 1
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |